Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistBased on limited metadata, this FDA Warning Letter issued to Vilvet Pharmaceutical on February 25, 2019, concerns drug manufacturing or product quality issues. Without access to the full letter text or specific subject line, the exact nature of the violations cannot be determined from the available information. The warning falls under FDA's drug regulatory jurisdiction, though the specific issuing office is not identified in the metadata provided. To understand the complete scope and specific compliance concerns, the full Warning Letter text would need to be reviewed.